Key facts
- This page summarizes Andrew J. Einhorn's Form 4 filing for RVL Pharmaceuticals plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jan 2022, 15:31.
Andrew J. Einhorn - 24 Jan 2022 Form 4 Insider Report for RVL Pharmaceuticals plc
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 24 Jan 2022
- Net transaction value
- -$10,856
- SEC form
- 4
- Accepted by SEC
- 26 Jan 2022, 15:31:55 UTC
- Prior SEC filing
- 08 Nov 2021
- Next SEC filing
- 15 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Klein, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew J. Einhorn filed Form 4 for RVL Pharmaceuticals plc on 26 Jan 2022.
Change
- Previous filing in this sequence was filed on 08 Nov 2021.
- Current net transaction value: -$10,856.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVLP
transaction
Ordinary Shares
Tax liability
- Transaction value
- $10,856
- Shares
- -9,607
- Change %
- -6.4%
- Price
- $1.13
- Shares after
- 141,473
- Date
- 24 Jan 2022
- Ownership
- Direct
RVLP
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 22,852
- Date
- 24 Jan 2022
- Ownership
- By family limited liability company
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Reporting Person is the sole managing member of the limited liability company and, as a result, may be deemed to beneficially own the ordinary shares held by the limited liability company. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.